Analgesic/abortive overuse and misuse in chronic daily headache

被引：24

作者：

Diener H.-C. ^{[1
]}

Katasarva Z. ^{[1
]}

机构：

[1] Department of Neurology, University Essen, Hufelandstr. 55, Essen

来源：

Current Pain and Headache Reports | 2001年 / 5卷 / 6期

关键词：

Chronic Daily Headache; Migraine; Migraine Attack; Sumatriptan; Zolmitriptan;

D O I：

10.1007/s11916-001-0061-7

中图分类号：

学科分类号：

摘要：

The frequent use (> 15 times/month) of medication for the treatment of acute migraine attacks may cause medication overuse headache. This kind of headache can be caused by the intake of combination analgesics, opioids, ergot alkaloids, and triptans. The delay between first intake and daily headache is shortest for triptans (1 to 2 years), longer for ergots (3 years), and longest for analgesics (5 years). Treatment includes drug withdrawal followed by structured acute therapy and initiation of migraine prophylactic treatment. © 2001, Current Science Inc.

引用

页码：545 / 550

页数：5

共 46 条

[11]

Andersson P.G., Ergotism—the clinical picture, Drug-induced Headache., pp. 16-19, (1988)

[12]

Bahra A., Walsh M., Menon S., Goadsby P.J., Does chronic daily headache arise de novo in association with regular analgesic use? [abstract], Cephalalgia, 20, (2000)

[13]

Lance F., Parkes C., Wilkinson M., Does analgesic abuse cause headache de novo?, Headache, 38, pp. 61-62, (1988)

[14]

Griffiths R.R., Woodson P.P., Reinforcing properties of caffeine: studies in humans and laboratory animals, Pharmacol Biochem Behav, 29, pp. 419-427, (1988)

[15]

Griffiths R.R., Woodson P.P., Caffeine physical dependence: a review of human and laboratory animal studies, Psychopharmacology, 94, pp. 437-451, (1988)

[16]

Silverman K., Evans S.M., Strain E.C., Griffiths R.R., Withdrawal syndrome after the double-blind cessation of caffeine consumption, N Engl J Med, 327, pp. 1109-1114, (1992)

[17]

van Dusseldorp M., Katan M.B., Headache caused by caffeine withdrawal among moderate coffee drinkers switched from ordinary to decaffeinated coffee: a 12 week double blind trial, Br Med J, 300, pp. 1558-1559, (1990)

[18]

Fisher M.A., Glass S., Butorphanol (Stadol): a study in problems of current drug information and control, Neurology, 48, pp. 1156-1160, (1997)

[19]

Ziegler D.K., Opiate and opioid use in patients with refractory headache, Cephalalgia, 14, pp. 5-10, (1994)

[20]

Saper J.R., Jones J.M., Ergotamine tartrate dependency: features and possible mechanisms, Clin Neuropharmacol, 9, pp. 244-256, (1986)

← 1 2 3 4 5 →